William Blair Issues Pessimistic Outlook for NAMS Earnings

NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) - Equities research analysts at William Blair lowered their Q1 2025 earnings per share estimates for NewAmsterdam Pharma in a research note issued to investors on Wednesday, February 26th. William Blair analyst M. Phipps now anticipates that the company will earn ($0.51) per share for the quarter, down from their prior forecast of ($0.49). The consensus estimate for NewAmsterdam Pharma's current full-year earnings is ($1.75) per share. William Blair also issued estimates for NewAmsterdam Pharma's Q2 2025 earnings at ($0.52) EPS, Q3 2025 earnings at ($0.54) EPS, Q4 2025 earnings at ($0.55) EPS, FY2025 earnings at ($2.11) EPS, Q1 2026 earnings at ($0.54) EPS, Q2 2026 earnings at ($0.53) EPS, Q3 2026 earnings at ($0.54) EPS, Q4 2026 earnings at ($0.56) EPS, FY2026 earnings at ($2.18) EPS, FY2027 earnings at ($2.49) EPS and FY2028 earnings at ($1.83) EPS.

Several other analysts have also issued reports on the company. HC Wainwright reiterated a "buy" rating and set a $48.00 price objective on shares of NewAmsterdam Pharma in a report on Tuesday, January 14th. Scotiabank increased their price objective on NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a "sector outperform" rating in a report on Thursday, February 27th. Royal Bank of Canada reiterated an "outperform" rating and set a $40.00 price objective on shares of NewAmsterdam Pharma in a report on Friday, January 24th. Finally, Needham & Company LLC lowered their target price on shares of NewAmsterdam Pharma from $46.00 to $42.00 and set a "buy" rating on the stock in a research report on Thursday, February 27th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $43.80.

Remove Ads

NewAmsterdam Pharma Stock Performance

Shares of NASDAQ:NAMS traded up $0.48 during midday trading on Monday, hitting $23.50. 2,519,534 shares of the stock were exchanged, compared to its average volume of 462,663. NewAmsterdam Pharma has a 52-week low of $15.19 and a 52-week high of $27.29. The business's fifty day simple moving average is $22.24 and its two-hundred day simple moving average is $20.43. The company has a market capitalization of $2.17 billion, a PE ratio of -9.04 and a beta of -0.06.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last announced its quarterly earnings data on Wednesday, February 26th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.47). The company had revenue of $12.77 million during the quarter, compared to analyst estimates of $3.30 million.

Institutional Investors Weigh In On NewAmsterdam Pharma

Hedge funds and other institutional investors have recently made changes to their positions in the business. GF Fund Management CO. LTD. acquired a new stake in shares of NewAmsterdam Pharma in the fourth quarter valued at about $50,000. National Bank of Canada FI acquired a new stake in shares of NewAmsterdam Pharma in the fourth quarter valued at about $51,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of NewAmsterdam Pharma in the fourth quarter valued at about $80,000. KLP Kapitalforvaltning AS acquired a new stake in shares of NewAmsterdam Pharma in the fourth quarter valued at about $154,000. Finally, Quarry LP grew its position in NewAmsterdam Pharma by 2,469.2% during the third quarter. Quarry LP now owns 6,500 shares of the company's stock worth $108,000 after buying an additional 6,247 shares in the last quarter. 89.89% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other NewAmsterdam Pharma news, major shareholder Nap B.V. Forgrowth sold 100,728 shares of the stock in a transaction on Wednesday, December 18th. The shares were sold at an average price of $26.10, for a total transaction of $2,629,000.80. Following the transaction, the insider now directly owns 10,908,502 shares of the company's stock, valued at $284,711,902.20. This represents a 0.91 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CAO Louise Frederika Kooij sold 150,000 shares of the firm's stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $20.37, for a total value of $3,055,500.00. Following the completion of the sale, the chief accounting officer now directly owns 15,000 shares in the company, valued at approximately $305,550. This represents a 90.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 554,927 shares of company stock valued at $13,446,287 over the last three months. 19.50% of the stock is currently owned by insiders.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.